Midostaurin
listen (MY-doh-STAW-rin)
This page contains brief information about midostaurin and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
Rydapt
FDA Approved
Yes
Use in Cancer
Midostaurin is approved to treat:
- Acute myeloid leukemia (AML). It is used with cytarabine and daunorubicin in newly diagnosed patients whose cancer has a mutation in the FLT3 gene.
- Aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia.
Midostaurin is also being studied in the treatment of other conditions and types of cancer.
More About Midostaurin
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Midostaurin Approved by FDA for Acute Myeloid Leukemia
Clinical Trials Accepting Patients
Find Clinical Trials for Midostaurin - Check for trials from NCI's list of cancer clinical trials now accepting patients.